Literature DB >> 16612645

[Chemotherapy of testicular cancer].

S Krege1, J T Hartmann, H Rübben.   

Abstract

Platinum-based polychemotherapy has increased the cure rate in testicular cancer dramatically: at first, chemotherapy was mainly used in advanced disease. Recently it has also become common in low-stage disease, though other therapeutic options are equivalent. Risk factors might help to find the right decision. The success of treatment in patients with metastatic disease results from the combination of chemotherapy and secondary surgery. High-dose chemotherapy for patients with poor prognosis or recurrent disease is being evaluated in clinical trials. Concerning the success in these stages prognostic factors are of special importance. Patients with advanced-stage nonseminoma need residual tumor resection after chemotherapy if no complete remission could be achieved. The therapist should be aware of the indication for and schedule of chemotherapy, its side effects, and supportive care.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16612645     DOI: 10.1007/s00120-006-1047-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  25 in total

1.  Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.

Authors:  K Fizazi; S Tjulandin; R Salvioni; J R Germà-Lluch; J Bouzy; D Ragan; C Bokemeyer; A Gerl; A Fléchon; J S de Bono; S Stenning; A Horwich; J Pont; P Albers; U De Giorgi; M Bower; A Bulanov; G Pizzocaro; J Aparicio; C R Nichols; C Théodore; J T Hartmann; H J Schmoll; S B Kaye; S Culine; J P Droz; C Mahé
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

2.  A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours.

Authors:  J-L Pico; G Rosti; A Kramar; H Wandt; V Koza; R Salvioni; C Theodore; G Lelli; W Siegert; A Horwich; M Marangolo; W Linkesch; G Pizzocaro; H-J Schmoll; J Bouzy; J-P Droz; P Biron
Journal:  Ann Oncol       Date:  2005-05-31       Impact factor: 32.976

3.  Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group.

Authors:  G C Toner; M R Stockler; M J Boyer; M Jones; D B Thomson; V J Harvey; I N Olver; H Dhillon; A McMullen; V J Gebski; J A Levi; R J Simes
Journal:  Lancet       Date:  2001-03-10       Impact factor: 79.321

4.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

5.  Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial.

Authors:  R T D Oliver; M D Mason; G M Mead; H von der Maase; G J S Rustin; J K Joffe; R de Wit; N Aass; J D Graham; R Coleman; S J Kirk; S P Stenning
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

6.  Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report.

Authors:  M H Cullen; S P Stenning; M C Parkinson; S D Fossa; S B Kaye; A H Horwich; S J Harland; M V Williams; R Jakes
Journal:  J Clin Oncol       Date:  1996-04       Impact factor: 44.544

7.  Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.

Authors:  H-J Schmoll; C Kollmannsberger; B Metzner; J T Hartmann; N Schleucher; P Schöffski; J Schleicher; O Rick; J Beyer; D Hossfeld; L Kanz; W E Berdel; R Andreesen; C Bokemeyer
Journal:  J Clin Oncol       Date:  2003-10-20       Impact factor: 44.544

8.  Results of a policy of surveillance in stage I testicular seminoma.

Authors:  P R Warde; M K Gospodarowicz; P J Goodman; J F Sturgeon; M A Jewett; C N Catton; H Richmond; G M Thomas; W Duncan; A J Munro
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-09-01       Impact factor: 7.038

9.  High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis.

Authors:  J Beyer; S Stenning; A Gerl; S Fossa; W Siegert
Journal:  Ann Oncol       Date:  2002-04       Impact factor: 32.976

10.  Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.

Authors:  S D Fosså; S P Stenning; A Gerl; A Horwich; P I Clark; P M Wilkinson; W G Jones; M V Williams; R T Oliver; E S Newlands; G M Mead; M H Cullen; S B Kaye; G J Rustin; P A Cook
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.